• Something wrong with this record ?

Rational design of PLA-based ASDs for pharmaceutical 3D printing: Insights from phase diagram modeling

ALV. Zumaya, A. Iemtsev, M. Fulem, F. Hassouna

. 2025 ; 208 (-) : 114657. [pub] 20250205

Language English Country Netherlands

Document type Journal Article

The integration of 3D printing into the pharmaceutical sciences opens new possibilities for personalized medicine. Poly(lactide) (PLA), a biodegradable and biocompatible polymer, is highly suitable for biomedical applications, particularly in the context of 3D printing. However, its processability often requires the addition of plasticizers. This study investigates the use of phase diagram modeling as a tool to guide the rational selection of plasticizers and to assess their impact on the thermodynamic and kinetic stability of PLA-based amorphous solid dispersions (ASDs) containing active pharmaceutical ingredients (APIs). Thermodynamic stability against API recrystallization was predicted based on the API solubility in PLA and Plasticizer-PLA carriers using the Conductor-like Screening Model for Real Solvents (COSMO-RS), while the kinetic stability of the ASDs was evaluated by modeling the glass transition temperatures of the mixtures. Two APIs, indomethacin (IND) and naproxen (NAP), with differing glass-forming abilities (i.e., recrystallization tendencies), and three plasticizers, triacetin (TA), triethyl citrate (TEC), and poly(L-lactide-co-caprolactone) (PLCL), were selected for investigation. The physical stability of ASD formulations containing 9 wt% API and plasticizer to PLA in two ratios, 10:81 and 20:71 w/w %, was monitored over time using differential scanning calorimetry and X-ray powder diffraction and compared with phase diagram predictions. All formulations were predicted to be thermodynamically unstable; however, those containing no plasticizer or with TEC and TA at 10 wt% were predicted to exhibit some degree of kinetic stability. Long-term physical studies corroborated these predictions. The correlation between the predicted phase behavior and long-term physical stability highlights the potential of phase diagram modeling as a tool for the rational design of ASDs in pharmaceutical 3D printing.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009645
003      
CZ-PrNML
005      
20250429134611.0
007      
ta
008      
250415e20250205ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejpb.2025.114657 $2 doi
035    __
$a (PubMed)39921011
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Zumaya, Alma Lucia Villela $u Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic
245    10
$a Rational design of PLA-based ASDs for pharmaceutical 3D printing: Insights from phase diagram modeling / $c ALV. Zumaya, A. Iemtsev, M. Fulem, F. Hassouna
520    9_
$a The integration of 3D printing into the pharmaceutical sciences opens new possibilities for personalized medicine. Poly(lactide) (PLA), a biodegradable and biocompatible polymer, is highly suitable for biomedical applications, particularly in the context of 3D printing. However, its processability often requires the addition of plasticizers. This study investigates the use of phase diagram modeling as a tool to guide the rational selection of plasticizers and to assess their impact on the thermodynamic and kinetic stability of PLA-based amorphous solid dispersions (ASDs) containing active pharmaceutical ingredients (APIs). Thermodynamic stability against API recrystallization was predicted based on the API solubility in PLA and Plasticizer-PLA carriers using the Conductor-like Screening Model for Real Solvents (COSMO-RS), while the kinetic stability of the ASDs was evaluated by modeling the glass transition temperatures of the mixtures. Two APIs, indomethacin (IND) and naproxen (NAP), with differing glass-forming abilities (i.e., recrystallization tendencies), and three plasticizers, triacetin (TA), triethyl citrate (TEC), and poly(L-lactide-co-caprolactone) (PLCL), were selected for investigation. The physical stability of ASD formulations containing 9 wt% API and plasticizer to PLA in two ratios, 10:81 and 20:71 w/w %, was monitored over time using differential scanning calorimetry and X-ray powder diffraction and compared with phase diagram predictions. All formulations were predicted to be thermodynamically unstable; however, those containing no plasticizer or with TEC and TA at 10 wt% were predicted to exhibit some degree of kinetic stability. Long-term physical studies corroborated these predictions. The correlation between the predicted phase behavior and long-term physical stability highlights the potential of phase diagram modeling as a tool for the rational design of ASDs in pharmaceutical 3D printing.
650    12
$a 3D tisk $7 D066330
650    12
$a polyestery $x chemie $7 D011091
650    12
$a změkčovadla $x chemie $7 D010968
650    12
$a indomethacin $x chemie $7 D007213
650    12
$a rozpustnost $7 D012995
650    _2
$a naproxen $x chemie $7 D009288
650    _2
$a krystalizace $7 D003460
650    _2
$a termodynamika $7 D013816
650    _2
$a triacetin $x chemie $7 D014215
650    _2
$a stabilita léku $7 D004355
650    _2
$a tranzitní teplota $7 D044366
650    _2
$a citráty $x chemie $7 D002951
650    _2
$a farmaceutická chemie $x metody $7 D002626
650    _2
$a farmaceutická technologie $x metody $7 D013678
650    _2
$a diferenciální skenovací kalorimetrie $x metody $7 D002152
650    _2
$a rozpouštědla $x chemie $7 D012997
655    _2
$a časopisecké články $7 D016428
700    1_
$a Iemtsev, Anton $u Department of Physical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic
700    1_
$a Fulem, Michal $u Department of Physical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: fulemm@vscht.cz
700    1_
$a Hassouna, Fatima $u Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: fatima.hassouna@vscht.cz
773    0_
$w MED00001640 $t European journal of pharmaceutics and biopharmaceutics $x 1873-3441 $g Roč. 208 (20250205), s. 114657
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39921011 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134606 $b ABA008
999    __
$a ok $b bmc $g 2311176 $s 1246726
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 208 $c - $d 114657 $e 20250205 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...